The Expression of Testin, Ki-67 and p16 in Cervical Cancer Diagnostics.
TES protein
antigen Ki-67
cervical cancer
immunohistochemistry
p16 protein
Journal
Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761
Informations de publication
Date de publication:
05 Jan 2023
05 Jan 2023
Historique:
received:
08
12
2022
revised:
29
12
2022
accepted:
02
01
2023
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
21
1
2023
Statut:
epublish
Résumé
Testin is a protein expressed in normal human tissues, being responsible, with other cytoskeleton proteins, for the proper functioning of cell−cell junction areas and focal adhesion plaques. It takes part in the regulation of actin filament changes during cell spreading and motility. Loss of heterozygosity in the testin-encoding gene results in altered protein expression in many malignancies, as partly described for cervical cancer. The aim of our study was the assessment of the immunohistochemical (IHC) expression of testin in cervical cancer and its analysis in regard to clinical data as well the expression of the Ki-67 antigen and p16 protein. Moreover, testin expression was assessed by Western blot (WB) in commercially available cell lines. The IHC analysis disclosed that the expression of testin inversely correlated with p16 (r = −0.2104, p < 0.0465) and Ki-67 expression (r = −0.2359, p < 0.0278). Moreover, weaker testin expression was observed in cancer cases vs. control ones (p < 0.0113). The WB analysis of testin expression in the cervical cancer cell lines corresponded to the IHC results and showed a weaker expression compared to that in the control cell line. When we compared the expression of testin in cervical cancer cell lines, we found a weaker expression in HPV-negative cell lines. In summary, we found that the intensity of testin expression and the number of positive cells inversely correlated with the expression of Ki-67 (a marker of proliferation) and p16 (a marker of cell cycle dysregulation). This study shows that the combined assessment of testin, Ki-67 and p16 expression may improve cervical cancer diagnostics.
Identifiants
pubmed: 36661518
pii: cimb45010032
doi: 10.3390/cimb45010032
pmc: PMC9857082
doi:
Types de publication
Journal Article
Langues
eng
Pagination
490-500Subventions
Organisme : National Science Center
ID : 2018/29/N/NZ5/01911
Références
Leuk Res. 1999 Mar;23(3):307-10
pubmed: 10071086
Front Oncol. 2022 Jan 24;11:815213
pubmed: 35141154
Genomics. 2000 Aug 15;68(1):1-12
pubmed: 10950921
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Carcinogenesis. 2010 Jan;31(1):27-36
pubmed: 19752007
Oncol Lett. 2016 Nov;12(5):3305-3311
pubmed: 27899997
APMIS. 2015 May;123(5):394-400
pubmed: 25720371
Anticancer Res. 1998 Jan-Feb;18(1A):453-8
pubmed: 9568119
Papillomavirus Res. 2019 Dec;8:100170
pubmed: 31176807
Adv Exp Med Biol. 2020;1279:1-8
pubmed: 32170669
Oncol Rep. 2019 Dec;42(6):2655-2669
pubmed: 31661141
Nat Rev Mol Cell Biol. 2004 Nov;5(11):920-31
pubmed: 15520811
Cancer Manag Res. 2019 Feb 22;11:1817-1827
pubmed: 30863187
Cancer Lett. 2021 Jan 1;496:104-116
pubmed: 33038491
Oncogene. 2001 May 17;20(22):2844-53
pubmed: 11420696
Hypertension. 2004 Apr;43(4):726-30
pubmed: 14967842
Cell Motil Cytoskeleton. 2004 Mar;57(3):133-42
pubmed: 14743347
Cells. 2019 Jun 21;8(6):
pubmed: 31234354
Infect Agent Cancer. 2017 Sep 30;12:50
pubmed: 29021820
J Cell Biol. 1988 Mar;106(3):761-71
pubmed: 2450098
ESMO Open. 2018 Jun 28;3(4):e000352
pubmed: 30018810
Cancer Epidemiol. 2019 Apr;59:123-128
pubmed: 30739069
Asian Pac J Cancer Prev. 2019 Nov 01;20(11):3259-3268
pubmed: 31759347
Cancer Manag Res. 2020 Sep 25;12:9067-9075
pubmed: 33061601
PLoS One. 2020 Jun 19;15(6):e0234873
pubmed: 32559232
Protoplasma. 2002 Feb;219(1-2):1-12
pubmed: 11926060
Lab Med. 2018 Mar 21;49(2):97-111
pubmed: 29378033
J Cell Sci. 2003 Mar 1;116(Pt 5):897-906
pubmed: 12571287
Int J Mol Sci. 2020 Dec 21;21(24):
pubmed: 33371204
Arch Pathol Lab Med. 2007 Sep;131(9):1343-9
pubmed: 17824788
Oncol Lett. 2019 Aug;18(2):1351-1355
pubmed: 31423197
Clin Cancer Res. 1995 Nov;1(11):1385-9
pubmed: 9815935
Am J Surg Pathol. 2001 Jul;25(7):884-91
pubmed: 11420459
J Cell Biol. 2003 Apr 14;161(1):33-9
pubmed: 12695497
Oncogene. 1997 Jun 19;14(24):2979-84
pubmed: 9205105
Mol Cancer. 2010 Jun 24;9:163
pubmed: 20573277
Clin Cancer Res. 1997 Jun;3(6):1009-16
pubmed: 9815778
Cancer Cytopathol. 2019 Mar;127(3):169-180
pubmed: 30811902
Med Sci Monit. 2014 Jun 14;20:980-7
pubmed: 24929083
Br J Cancer. 1997;76(12):1567-71
pubmed: 9413943
Nature. 2012 Aug 30;488(7413):S2-3
pubmed: 22932437
Oncol Rep. 2017 Feb;37(2):1027-1035
pubmed: 28000866
Cancer Sci. 2012 Dec;103(12):2092-101
pubmed: 22957844
Pathol Oncol Res. 2019 Oct;25(4):1279-1284
pubmed: 30357755
BMC Cancer. 2019 Mar 27;19(1):271
pubmed: 30917784
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008